Search: onr:"swepub:oai:DiVA.org:lnu-37924" >
BCR-ABL1 Compound M...
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
-
- Zabriskie, Matthew S. (author)
- University of Utah, USA
-
- Eide, Christopher A. (author)
- Oregon Health & Science University, USA;Howard Hughes Medical Institute, USA
-
- Tantravahi, Srinivas K. (author)
- University of Utah, USA
-
show more...
-
- Vellore, Nadeem A. (author)
- University of Utah, USA
-
- Estrada, Johanna (author)
- University of Utah, USA
-
- Nicolini, Franck E. (author)
- Centre Hospitalier Lyon Sud, France
-
- Khoury, Hanna J. (author)
- Emory University, USA
-
- Larson, Richard A. (author)
- University of Chicago, USA
-
- Konopleva, Marina (author)
- University of Texas, USA
-
- Cortes, Jorge E. (author)
- University of Texas, USA
-
- Kantarjian, Hagop (author)
- University of Texas, USA
-
- Jabbour, Elias J. (author)
- University of Texas, USA
-
- Kornblau, Steven M. (author)
- University of Texas, USA
-
- Lipton, Jeffrey H. (author)
- University of Toronto, Canada
-
- Rea, Delphine (author)
- Hospital Saint-Louis, France
-
- Stenke, Leif (author)
- Karolinska Institutet
-
- Barbany, Gisela (author)
- Karolinska Institutet
-
- Lange, Thoralf (author)
- University of Leipzig, Germany
-
- Hernandez-Boluda, Juan-Carlos (author)
- Hospital Clı´nico Universitario, Spain
-
- Ossenkoppele, Gert J. (author)
- VU University Medical Center, Netherlands
-
- Press, Richard D. (author)
- Oregon Health & Science University, USA
-
- Chuah, Charles (author)
- Singapore General Hospital, Singapore
-
- Goldberg, Stuart L. (author)
- John Theurer Cancer Center at Hackensack University Medical Center, USA
-
- Wetzler, Meir (author)
- Roswell Park Cancer Institute, USA
-
- Mahon, Francois-Xavier (author)
- Centre Hospitalier Universitaire de Bordeaux, France
-
- Etienne, Gabriel (author)
- Institut Bergonie, France
-
- Baccarani, Michele (author)
- University of Bologna, Italy
-
- Soverini, Simona (author)
- University of Bologna, Italy
-
- Rosti, Gianantonio (author)
- University of Bologna, Italy
-
- Rousselot, Philippe (author)
- Université de Versailles, France
-
- Friedman, Ran (author)
- Linnéuniversitetet,Institutionen för kemi och biomedicin (KOB),CCBG;Linnaeus Ctr Biomat Chem, BMC
-
- Deininger, Marie (author)
- University of Utah, USA
-
- Reynolds, Kimberly R. (author)
- University of Utah, USA
-
- Heaton, William L. (author)
- University of Utah, USA
-
- Eiring, Anna M. (author)
- University of Utah, USA
-
- Pomicter, Anthony D. (author)
- University of Utah, USA
-
- Khorashad, Jamshid S. (author)
- University of Utah, USA
-
- Kelley, Todd W. (author)
- University of Utah, USA
-
- Baron, Riccardo (author)
- University of Utah, USA
-
- Druker, Brian J. (author)
- Oregon Health & Science University Knight Cancer Institute, USA;Howard Hughes Medical Institute, USA
-
- Deininger, Michael W. (author)
- University of Utah, USA
-
- O'Hare, Thomas (author)
- University of Utah, USA
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2014
- 2014
- English.
-
In: Cancer Cell. - : Elsevier BV. - 1535-6108 .- 1878-3686. ; 26:3, s. 428-442
- Related links:
-
http://www.sciencedi...
-
show more...
-
http://www.cell.com/...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+) leukemia, including the recalcitrant BCR-ABL1(T315I) mutant. However, emergence of compound mutations in a BCR-ABL1 allele may confer ponatinib resistance. We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer varying resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib, and bosutinib. T315I-inclusive compound mutants confer high-level resistance to TKIs, including ponatinib. In vitro resistance profiling was predictive of treatment outcomes in Ph+ leukemia patients. Structural explanations for compound mutation-based resistance were obtained through molecular dynamics simulations. Our findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Biomedical Sciences
- Biomedicinsk vetenskap
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Zabriskie, Matth ...
-
Eide, Christophe ...
-
Tantravahi, Srin ...
-
Vellore, Nadeem ...
-
Estrada, Johanna
-
Nicolini, Franck ...
-
show more...
-
Khoury, Hanna J.
-
Larson, Richard ...
-
Konopleva, Marin ...
-
Cortes, Jorge E.
-
Kantarjian, Hago ...
-
Jabbour, Elias J ...
-
Kornblau, Steven ...
-
Lipton, Jeffrey ...
-
Rea, Delphine
-
Stenke, Leif
-
Barbany, Gisela
-
Lange, Thoralf
-
Hernandez-Boluda ...
-
Ossenkoppele, Ge ...
-
Press, Richard D ...
-
Chuah, Charles
-
Goldberg, Stuart ...
-
Wetzler, Meir
-
Mahon, Francois- ...
-
Etienne, Gabriel
-
Baccarani, Miche ...
-
Soverini, Simona
-
Rosti, Giananton ...
-
Rousselot, Phili ...
-
Friedman, Ran
-
Deininger, Marie
-
Reynolds, Kimber ...
-
Heaton, William ...
-
Eiring, Anna M.
-
Pomicter, Anthon ...
-
Khorashad, Jamsh ...
-
Kelley, Todd W.
-
Baron, Riccardo
-
Druker, Brian J.
-
Deininger, Micha ...
-
O'Hare, Thomas
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Cancer Cell
- By the university
-
Linnaeus University
-
Karolinska Institutet